|
Back to products
Browse products
Approved anticancer agents
Anticancer agents in trials
Anticancer agents
in preclinical trials
Anticancer molecular libraries
Other drug agents
Drug intermediates
Bio-reagents and biochemicals
|
MedKoo product information:
Thiarabine
|
MedKoo Code#: 205644
|
|
Name: Thiarabine
|
|
CAS#: 6599-17-7
Synonym: Thiarabine;
2(1H)-Pyrimidinone, 4-amino-1-(4-thio-β-D-arabinofuranosyl)-;
Cytosine, 1-(4-thio-β-D-arabinofuranosyl)- (8CI); 4'-Thio-1-β-D-arabinofuranosylcytosine;
4'-Thioaracytidine; OSI 7836; Thio-Cytarabine
IUPAC/Chemical name:
4-amino-1-((2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrothiophen-2-yl)pyrimidin-2(1H)-one
|
|
Chemical structure
|
Theoretical analysis
|
|

|
MedKoo Code#: 205644
Name: Thiarabine
CAS#: 6599-17-7
Chemical Formula: C9H13N3O4S
Exact Mass: 259.06268
Molecular Weight: 259.28
Elemental Analysis: C, 41.69; H, 5.05; N,
16.21; O, 24.68; S, 12.37
|
|
Availability and price:
This agent is
not in stock, which may be available through custom synthesis.
To inquire quotation and lead time or to ask questions, please send email to
sales@medkoo.com to describe your needs. A representative
will respond your email shortly. We offer big discount for orders of bulk quantities.
|
|
Information about this agent
|
thiarabine is a
analog of antimetabolite cytarabine (ara-C), with potential
antineoplastic activity. Upon administration, thiarabine (T-araC) is
phosphorylated to the triphosphate form T-araCTP and competes with
cytidine for incorporation into DNA. This results in an inhibition of
DNA replication and RNA synthesis, chain termination and may eventually
decrease tumor cell proliferation. Compared to ara-C, T-araC appears to
have a longer half-life and has a higher efficacy. Check for
active clinical trials or
closed clinical trials using this agent. (NCI
Thesaurus).
Current developer:
Access Pharmaceuticals
1. New nucleoside analogs for patients with
hematological malignancies By Robak, Tadeusz From Expert Opinion on
Investigational Drugs (2011), 20(3), 343-359.
2. Use of alkylphosphocholines in combination with antimetabolites for
the treatment of benign and malignant oncoses in humans and mammals By
Engel, Juergen; Guenther, Eckhard; Sindermann, Herbert; Aicher, Babette
From U.S. Pat. Appl. Publ. (2011), US 20110028421 A1 20110203.
3. Inhibition of herpesvirus replication by 5-substituted
4'-thiopyrimidine nucleosides By Prichard, Mark N.; Quenelle, Debra C.;
Hartline, Caroll B.; Harden, Emma A.; Jefferson, Geraldine; Frederick,
Samuel L.; Daily, Shannon L.; Whitley, Richard J.; Tiwari, Kamal N.;
Maddry, Joseph A.; et al From Antimicrobial Agents and Chemotherapy
(2009), 53(12), 5251-5258.
4. Enhancement of the in vivo antitumor activity of clofarabine by
1-β-d-[4-thio-arabinofuranosyl]-cytosine By Parker, William B.; Shaddix,
Sue C.; Gilbert, Karen S.; Shepherd, Rodney V.; Waud, William R. From
Cancer Chemotherapy and Pharmacology (2009), 64(2), 253-261.
5. Activities of certain 5-substituted 4'-thiopyrimidine nucleosides
against orthopoxvirus infections By Kern, Earl R.; Prichard, Mark N.;
Quenelle, Debra C.; Keith, Kathy A.; Tiwari, Kamal N.; Maddry, Joseph
A.; Secrist, John A., III From Antimicrobial Agents and Chemotherapy
(2009), 53(2), 572-579.
6. Method for treating and preventing arthritis By Secrist, John A.;
Waud, William R.; Qu, Zhican; Cui, Xiangmin From U.S. Pat. Appl. Publ.
(2008), US 20080234275 A1 20080925.
7. Cytotoxic activities of nucleoside and nucleobase analog drugs in
malignant mesothelioma: Characterization of a novel nucleobase transport
activity By Damaraju, Deepti; Damaraju, Vijaya L.; Brun, Miranda;
Mowles, Delores; Kuzma, Michelle; Berendt, Richard C.; Sawyer, Michael
B.; Cass, Carol E. From Biochemical Pharmacology (2008), 75(10),
1901-1911.
8. Nucleosides as anticancer agents: from concept to the clinic By
Secrist, John A., III From Nucleic Acids Symposium Series (2005), (49),
15-16.
9. Antiangiogenic activity of 4'-thio-β-D-arabinofuranosylcytosine By
Roy, Anshu M.; Tiwari, Kamal N.; Parker, William B.; Secrist, John A.,
III; Li, Rongbao; Qu, Zhican From Molecular Cancer Therapeutics (2006),
5(9), 2218-2224.
10. A phase I, first in man study of OSI-7836 in patients with advanced
refractory solid tumors: IND.147, a study of the Investigational New
Drug Program of the National Cancer Institute of Canada Clinical Trials
Group By Goss, G.; Siu, L. L.; Gauthier, I.; Chen, E. X.; Oza, A. M.;
Goel, R.; Maroun, J.; Powers, J.; Walsh, W.; Maclean, M.; et al From
Cancer Chemotherapy and Pharmacology (2006), 58(5), 703-710.
11. The role of human nucleoside transporters in cellular uptake of
4'-thio-β-D-arabinofuranosylcytosine and β-D-arabinosylcytosine By
Clarke, Marilyn L.; Damaraju, Vijaya L.; Zhang, Jing; Mowles, Delores;
Tackaberry, Tracey; Lang, Thach; Smith, Kyla M.; Young, James D.;
Tomkinson, Blake; Cass, Carol E. From Molecular Pharmacology (2006),
70(1), 303-310.
12. A phase I study of a new nucleoside analogue, OSI-7836, using two
administration schedules in patients with advanced solid malignancies By
Lee, Chooi P.; de Jonge, Maja J. A.; O'Donnell, Anne E.; Schothorst,
Kristel L.; Hanwell, Janet; Chick, Jon B.; Brooimans, Rik A.; Adams,
Laurel M.; Drolet, Daniel W.; de Bono, Johann S.; et al From Clinical
Cancer Research (2006), 12(9), 2841-2848.
13. Long intracellular retention of 4'-thio-arabinofuranosylcytosine
5'-triphosphate as a critical factor for the anti-solid tumor activity
of 4'-thio-arabinofuranosylcytosine By Someya, Hitoshi; Waud, William
R.; Parker, William B. From Cancer Chemotherapy and Pharmacology (2006),
57(6), 772-780.
14. Safety Assessment of 4'-Thio-β-D-Arabinofuranosylcytosine in the
Beagle Dog Suggests a Drug-Induced Centrally Mediated Effect on the
Hypothalamic-Pituitary-Adrenal Axis By Colagiovanni, Dorothy B.; Drolet,
Daniel W.; Dihel, Larry; Meyer, Dennis J.; Hart, Karen; Wolf, Julie From
International Journal of Toxicology (2006), 25(2), 119-126.
15. Mechanism of action of 4'-thio-beta-D-arabinofuranosylcytosine By
Someya, Hitoshi No Corporate Source data available (2005), 115 pp..
English, Database: CAPLUS Substances Reactions ~0 Citings Full Text Link
0 Comments 0 Tags
16. c-Abl-independent p73 stabilization during gemcitabine- or
4'-thio-β-D-arabinofuranosylcytosine-induced apoptosis in wild-type and
p53-null colorectal cancer cells By Thottassery, Jaideep V.; Westbrook,
Louise; Someya, Hitoshi; Parker, William B. From Molecular Cancer
Therapeutics (2006), 5(2), 400-410.
17. Chemical and enzymatic synthesis of
4'-thio-β-D-arabinofuranosylcytosine monophosphate and triphosphate By
Fowler, A. S.; Tiwari, K. N.; Campbell, S. R.; Secrist, J. A., III From
Nucleosides, Nucleotides & Nucleic Acids (2005), 24(5-7), 533-537.
18. Bone marrow proliferation assay By Koratich, Michael S.; May,
Richard D. From PCT Int. Appl. (2005), WO 2005026380 A2 20050324.
19. Incorporation of OSI-7836 into DNA of Calu-6 and H460 xenograft
tumors By Richardson, Frank; Black, Chris; Richardson, Katherine;
Franks, April; Wells, Edward; Karimi, Susan; Sennello, Gina; Hart,
Karen; Meyer, Denny; Emerson, David; et al From Cancer Chemotherapy and
Pharmacology (2005), 55(3), 213-221.
20. Polymerization of the triphosphates of AraC, 2',2'-difluorodeoxycytidine
(dFdC) and OSI-7836 (T-araC) by human DNA polymerase α and DNA primase
By Richardson, Katherine A.; Vega, Tanya P.; Richardson, Frank C.;
Moore, Chad L.; Rohloff, John C.; Tomkinson, Blake; Bendele, Raymond A.;
Kuchta, Robert D. From Biochemical Pharmacology (2004), 68(12),
2337-2346.
21. Preparation of bioreductively activated prodrugs of
antiproliferative agents By Davis, Peter David; Naylor, Matthew
Alexander; Thomson, Peter; Everett, Steven Albert; Stratford, Michael
Richard Lacey; Wardman, Peter From PCT Int. Appl. (2004), WO 2004085421
A2 20041007.
22. Preclinical antitumor activity of 4'-thio-β-D-arabinofuranosylcytosine
(4'-thio-ara-C) By Waud, William R.; Gilbert, Karen S.; Shepherd, Rodney
V.; Montgomery, John A.; Secrist, John A. From Cancer Chemotherapy and
Pharmacology (2003), 51(5), 422-426.
23. Phosphorylation of 4'-thio-β-D-arabinofuranosylcytosine and its
analogs by human deoxycytidine kinase By Someya, Hitoshi; Shaddix, Sue
C.; Tiwari, Kamal N.; Secrist, John A., III; Parker, William B. From
Journal of Pharmacology and Experimental Therapeutics (2003), 304(3),
1314-1322.
24. Synthesis and structure activity relationships of 5-substituted -
4'-thio-β-D-arabinofuranosylcytosines By Tiwari, Kamal N.; Shortnacy-Fowler,
Anita T.; Cappellacci, Loredana; Waud, William R.; Parker, William B.;
Montgomery, John A.; Secrist, John A., III From Nucleosides, Nucleotides
& Nucleic Acids (2000), 19(10-12), 2005-2017.
25. Metabolism of 4'-thio-β-d-arabinofuranosylcytosine in CEM cells By
Parker, W. B.; Shaddix, S. C.; Rose, L. M.; Waud, W. R.; Shewach, D. S.;
Tiwari, K. N.; Secrist, J. A. From Biochemical Pharmacology (2000),
60(12), 1925-1932.
26. Synthesis of 4'-thio-β-D-arabinofuranosylcytosine (4'-thio-ara-C)
and comparison of its anticancer activity with that of ara-C By Tiwari,
Kamal N.; Shortnacy-Fowler, Anita T.; Cappellacci, Loredana; Parker,
William B.; Waud, William R.; Montgomery, John A.; Secrist, John A., III
From Nucleosides, Nucleotides & Nucleic Acids (2000), 19(1 & 2),
329-340.
27. Preparation of thioarabinofuranosyl nucleosides as antitumors By
Secrist, John A., III; Tiwari, Kamal N.; Montgomery, John A. From PCT
Int. Appl. (2000), WO 2000004866 A2 20000203.
28. Preparation and antitumor activity of 4'-thio analogs of
2,2'-anhydro-1-β-D-arabinofuranosylcytosine By Ototani, N.; Whistler,
Roy L. From Journal of Medicinal Chemistry (1974), 17(5), 535-7.
29. 4-Thio-D-arabinofuranosylpyrimidine nucleosides By Whistler, Roy L.;
Doner, Landis W.; Nayak, Govindraj U. From Journal of Organic Chemistry
(1971), 36(1), 108-10.
|
Contact MedKoo:
Email:
sales@medkoo.com
(Keyword; CAS#; MedKoo code#)
|